Summary Keywords GLP-1, Alzheimers disease, Parkinsons disease, neuroinflammation, amyloid beta, mitochondrial dysfunction, brain glucose hypometabolism, insulin resistance Citation Reich N and Hlscher C (2022) The neuroprotective effects of glucagon-like peptide 1 in Alzheimers and Parkinsons disease: An in-depth review
Nearly all testers saw fewer breakages, saying their hair looked and felt thicker and fuller after the trial period
All of this is cash-pay
However, ongoing monitoring for potential side effects, such as pancreatitis or gallbladder disease, is recommended
Looking for deeper support
Ongoing studies aim to unravel the full range of health benefits it may offer, from supporting mental health to enhancing athletic performance